Novartis returns Debiopharm's alisporivir after Hep C exit
This article was originally published in Scrip
Executive Summary
Novartis has returned all rights of Debiopharm's hepatitis C virus (HCV) compound alisporivir in line with the company's decision to pull out of HCV.